Puma Biotechnology 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Puma Biotechnology reported total revenue of $55.1 million for Q3 2026, including net product revenue of $54.1 million, compared with $53.6 million in Q2 2026 and $51.9 million in Q3 2025.
- Net product revenue included approximately $1.5 million of inventory drawdown; reported NERLYNX sales included U.S. net sales and product supply revenue to ex-U.S. partners.
- U.S. demand was 2,899 bottles, down approximately 3% quarter over quarter and up 5% year over year; ex-factory bottle sales were 2,818, down approximately 4% quarter over quarter and year over year.
- The specialty distributor channel represented 39% of Q3 2026 business and grew 19% year over year, driven by increased group purchasing organization and 340B purchasing.
- GAAP net income was $6 million, or $0.11 per diluted share, compared with $8.2 million, or $0.16 per share, in Q2 2026; non-GAAP net income was $8 million, or $0.15 per basic undiluted share.
- Royalty revenue was $0.9 million, compared with $2.9 million in Q2 2026; Puma recorded a $2.1 million cumulative reduction to royalty revenue after third-party data showed generic versions of Nerlynx in China had reached a specified market-share threshold during 2025.
- Puma reported $14.7 million of cash generated in Q3 2026, was debt-free after its final quarterly principal loan payment in Q2 2026, and had $108.5 million in cash, cash equivalents, and marketable securities as of September 30th, 2026.
- The company has three ongoing Phase 2 studies of alacertib: ALISCA-BREAST 1, ALISCA-LUNG 1, and ALISCA-LUNG 2.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon. My name is Latanya, and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question-and-answer session. If you would like to ask a question during that time, simply press the star key, then the number 1 on your telephone keypad. If you would like to withdraw your question, please press star two. If you should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin the conference.
Thank you, Latanya. Good afternoon, and welcome to Puma's conference call to discuss our earnings results for the third quarter of 2026. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President, and Chairman of the Board of Puma Biotechnology; Maximo Nougues, Chief Financial Officer; Heather Blaber, Senior Vice President of Marketing; and Roger Storms, Senior Vice President of Sales. After the close today, Puma issued a news release detailing earnings results for the third quarter of 2026. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and investor sections of our website at pumabiotechnology.com. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days.
Today's conference call will include statements about Puma's future expectations, plans, and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties, and actual events and results may differ from those expressed in these forward-looking statements. For a full discussion of these risks and uncertainties, please review our periodic and current reports filed with the SEC from time to time, including our annual report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this live conference call, November 5, 2026. Puma undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law.
During today's call, we may refer to certain non-GAAP financial measures that involve adjustments to our GAAP figures. We believe these non-GAAP metrics may be useful to investors as a supplement to, but not a substitute for, our GAAP financial measures. Please refer to our third quarter 2026 earnings release for a reconciliation of our GAAP to non-GAAP results. I will now turn the call over to Alan.
Thank you, Marianne, and thank you all for joining our call today. Today, Puma reported total revenue for the third quarter of 2026 of $55.1 million. Total revenue includes product revenue net, which consists entirely of NERLYNX sales, as well as royalties from our sub-licensees. Product revenue net was $54.1 million in the third quarter of 2026, an increase from $53.6 million reported in Q2 2026 and $51.9 million reported in Q3 2025. As a reminder to investors, Puma reported NERLYNX sales includes both U.S. net sales of NERLYNX and product supply revenues of NERLYNX to Puma's ex-U.S. partners. Product revenue for the third quarter of 2026 included approximately $1.5 million of inventory drawdown at our specialty pharmacies and specialty distributors. Royalty revenue was slightly below $1 million in the third quarter of 2026, compared to $2.9 million in Q2 2026 and $2.6 million in Q2 2025.
We reported 2,818 bottles of NERLYNX sold in the third quarter of 2026, compared to 2,929 bottles sold in Q2 2026. In Q3 2026, we estimate that inventory decreased by 82 bottles. In Q1 2026, new prescriptions were down approximately 13% compared to Q2 2026, and total prescriptions were down approximately 5% compared to Q2 2026. Roger will provide further details in his comments and slides. I will now provide updates from Puma's ongoing phase II trials of alisertib in small cell lung cancer and HER2-negative ER-positive breast cancer, also referred to as ALISCA-Lung1, ALISCA-Lung2, and ALISCA-Breast1. Heather Blaber and Roger Storms will add additional color on NERLYNX commercial activities. Maximo Nougues will follow with highlights of the key components of our financial statements for the third quarter of 2026. As investors are aware, Puma currently has three ongoing phase II studies of our investigational drug, alisertib.
ALISCA-Breast1, a phase II trial of alisertib in combination with endocrine treatment in patients with HER2-negative, hormone receptor-positive recurrent or metastatic breast cancer. ALISCA-Lung1, a phase II study looking at the efficacy of alisertib monotherapy in patients with small cell lung cancer. ALISCA-Lung2, a phase II trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. As a reminder, the ALISCA-Breast1 trial investigates alisertib in combination with endocrine treatment, consisting of either anastrozole, exemestane, letrozole, fulvestrant, or tamoxifen in patients with HER2-negative, hormone receptor-positive, recurrent, or metastatic breast cancer. Patients must be chemotherapy-naive in the recurrent or metastatic setting, have had previous treatment with a CDK4/6 inhibitor, and have received at least two prior lines of endocrine therapy to be eligible for the trial.
Patients were initially dosed with alisertib, given at either 30 milligrams, 40 milligrams, or 50 milligrams twice daily on days one to three, eight to 10, and 15 to 17 of a 28-day cycle, in combination with endocrine therapy of the investigator's choice. Patients must not have previously been treated with the endocrine treatment in the metastatic setting that will be given in combination with alisertib in the trial. Interim data from this trial was presented on the company's first quarter conference call. As discussed during that presentation, the company believes that the data obtained to date from ALISCA-Breast1 is providing a preliminary indication of potentially better activity in patients with biomarkers where the Aurora kinase pathway plays a role.
Based on feedback that we have received from breast cancer key opinion leaders on this interim data, the trial has been amended such that we are only continuing enrollment in the 40 milligram and 50 milligram dose groups only. We began enrollment under that amended protocol during Q3. We are anticipating that updated interim data from the ALISCA-Breast1 study, including longer patient follow-up, will be presented at the San Antonio Breast Cancer Symposium in December. Based on our initial analysis of this data, we believe that the data from ALISCA-Breast1 is supportive of a phase III trial of alisertib in patients with HER2-negative, hormone receptor-positive, recurrent, or metastatic breast cancer. The company is looking to engage with global regulatory authorities regarding the design of this phase III trial in the first half of 2027.
With respect to the ALISCA-Lung1 study, as investors are aware, Puma has an ongoing phase II trial of our investigational drug, alisertib, to investigate the efficacy of alisertib monotherapy in patients with extensive stage small cell lung cancer. Interim data from this trial was presented on the company's first quarter earnings call. As discussed during that presentation, the company believes that the data obtained to date from ALISCA-Lung is providing a preliminary indication of potentially better activity in patients with biomarkers where the Aurora kinase pathway plays a role. As was also discussed on the call, the company previously amended the trial to increase the dose from 50 milligrams BID to 60 milligrams BID. Dosing in this trial was further increased to 70 milligrams BID, and the company is currently enrolling patients at the 70 milligram BID dose level.
Puma also initiated a second trial of alisertib in advanced small cell lung cancer, ALISCA-Lung2, where alisertib is given in combination with paclitaxel, similar to the phase II randomized trial that was previously published in the Journal of Thoracic Oncology in September 2026. The company anticipates that they will have additional interim data from the ALISCA-Lung1 trial and initial data from ALISCA-Lung2 in 2027. As mentioned on prior earnings calls and in response to investor questions, Puma continues to evaluate several commercial stage and development stage drugs to potentially in-license or acquire that would allow the company to diversify itself and leverage Puma's existing R&D, regulatory, and commercial infrastructure. The company will keep investors updated on this as it progresses. I will now turn the call over to Heather Blaber for an update on our marketing initiatives.
Roger Storms will follow with a review of our commercial performance during the quarter.
Thank you, Alan. I appreciate the opportunity to share some additional insights into our marketing strategy. The marketing team is focused on continued awareness of both clinical data for NERLYNX, as well as reinforcing the continued unmet need in HER2-positive early-stage breast cancer after adjuvant therapy. We continue to invest in market research to help us understand and validate the most effective ways to communicate our data with healthcare professionals through both personal and non-personal promotion. Our strategy is focused on increasing awareness of our dual indication in HER2-positive breast cancer. We believe NERLYNX plays an important role in the early stage by reducing the risk of recurrence and in the metastatic setting by helping protect against progression.
Not only do physicians who have experience with NERLYNX continue to identify appropriate patients that could benefit from additional therapy post-adjuvant treatment, but we continue to adopt new prescribers year over year who recognize the unmet need in HER2-positive early-stage breast cancer and how NERLYNX may help their patients reduce their risk of recurrence. In summary, we are excited and committed to engage with more oncologists and support their patients diagnosed with HER2-positive breast cancer in both the early and metastatic setting. I will now turn the call over to Roger Storms to provide an overview on the commercial performance for the second quarter.
Thank you, Heather, and thanks to everyone for joining our third quarter earnings call. Before I move into the commercial review, just a reminder that I will be making forward-looking statements. The sales team remains committed to expanding the appropriate use of NERLYNX, with a primary emphasis on patients at elevated risk of recurrence. The team continues to strengthen clinical education and healthcare provider engagement through non-personal promotional initiatives while leveraging patient support resources to encourage treatment adherence, persistence, and successful completion of NERLYNX therapy. Let me now transition to some of the commercial slides. We will provide some additional specifics around performance. Slide three is an illustration of our distribution model, which is broken out into the specialty pharmacy channel and the specialty distributor or in-office dispensing channel.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
